RTTNews | Sep 29, 2021 10:58AM EDT

10:57 Wednesday, September 29, 2021 (RTTNews.com) - Shares of genome editing company Editas Medicine, Inc. (EDIT) are down 13 percent on Wednesday's trading despite the company announcing positive initial clinical data from its ongoing, open label Phase 1/2 BRILLIANCE clinical trial of EDIT-101.

EDIT-101 is being developed for the treatment of blindness due to Leber congenital amaurosis 10 or LCA10, a CEP290-related retinal degenerative disorder.

Currently at $44.58, the stock has traded between $27.01 and $99.95 during the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3229135/editas-medicine-slips-13-despite-positive-data-on-edit-101-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved